ArticleTransfusion2025
The prevalence and timing of seroconversion during pregnancy-A retrospective study to enable safe transfusion.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring pregnancy, exposure to fetal red blood cell antigens can trigger alloimmunization. To enable safe transfusion of compatible blood for pregnant individuals where urgent surgery might be necessary, blood bank standards mandate a valid blood type and antibody screening every 72 h ("3-day rule"). This practice requires frequent blood drawings contributing to patient discomfort and costs. To investigate if this practice is required, we evaluated the proportion of pregnant individuals who develop clinically significant alloantibodies within 72 h of a previous negative antibody screen. STUDY DESIGN AND
methodsRetrospective cohort of RhD-positive pregnant individuals with initial negative antibody screens, undergoing repeated screens at variable intervals. Seroconversion rates were compared with healthy male blood donors. Characteristics of pregnant individuals with and without seroconversion were analyzed.
resultsAmong 8659 RhD-positive pregnant individuals with initial negative antibody screens, 56 (0.6%) converted to a positive antibody screen, while only 15 (0.2%) developed clinically significant alloantibodies. Of these 15, only one converted within 3 days of testing, while others converted within 5-95 days. Two of the 15 women received a blood transfusion, 8-97 days before seroconversion. No male donors seroconverted during 9 months of follow up. Pregnant individuals with seroconversion were more likely to have systemic lupus erythematosus and antiphospholipid antibody syndrome. DISCUSSION: Only one pregnant individual developed clinically significant alloantibodies within 72 h of a negative screening, compared to none of the control group. For pregnant individuals without recent transfusion, extending antibody screening intervals to 1 week appears safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.